Paperpal Prime Logo

PSORIASIS-TARGETS AND THERAPY : Impact Factor & More

eISSN: 2230-326XpISSN: 2230-326X
JournalOpen Access
Recommended pre-submission checks
Powered by Paperpal by Editage

PSORIASIS-TARGETS AND THERAPY Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • DOAJ DOAJ
Overview
Publisher DOVE MEDICAL PRESS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2390
Publication Time16
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2011
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 16
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in PSORIASIS-TARGETS AND THERAPY ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in PSORIASIS-TARGETS AND THERAPY

Impact of Psoriasis on Patient Well-Being Across Life Stages: A Cross-Sectional Survey (Inpsight Working Group)
  • 29 Jul 2026
  • Psoriasis: Targets and Therapy
Long-Term Effectiveness of Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: A 104-week Real-World Clinical and Ultrasound Study
  • 22 Jul 2026
  • Psoriasis: Targets and Therapy
Genotype\u2013Phenotype Correlations and Clinical Outcomes of Spesolimab in Acrodermatitis Continua of Hallopeau: A Multicenter Retrospective Cohort Study
  • 13 Jul 2026
  • Psoriasis: Targets and Therapy
Clinical Characteristics, Healthcare Resource Utilization, and Costs of Patients with Generalized Pustular Psoriasis in Taiwan: A National Claims Database Study
  • 26 Jun 2026
  • Psoriasis: Targets and Therapy
Inflammaging and Senescence-Associated Secretory Phenotype (SASP) in Psoriasis \u2013 A Narrative Review of Potential Mechanisms and Anti-Inflammaging Strategies
  • 28 May 2026
  • Psoriasis: Targets and Therapy
Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy
  • 27 May 2026
  • Psoriasis: Targets and Therapy
Impact of Psoriasis on Patient Well-Being Across Life Stages: A Cross-Sectional Survey (Inpsight Working Group)
  • 29 Jul 2026
  • Psoriasis: Targets and Therapy
Long-Term Effectiveness of Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: A 104-week Real-World Clinical and Ultrasound Study
  • 22 Jul 2026
  • Psoriasis: Targets and Therapy
Genotype\u2013Phenotype Correlations and Clinical Outcomes of Spesolimab in Acrodermatitis Continua of Hallopeau: A Multicenter Retrospective Cohort Study
  • 13 Jul 2026
  • Psoriasis: Targets and Therapy
Clinical Characteristics, Healthcare Resource Utilization, and Costs of Patients with Generalized Pustular Psoriasis in Taiwan: A National Claims Database Study
  • 26 Jun 2026
  • Psoriasis: Targets and Therapy
Inflammaging and Senescence-Associated Secretory Phenotype (SASP) in Psoriasis \u2013 A Narrative Review of Potential Mechanisms and Anti-Inflammaging Strategies
  • 28 May 2026
  • Psoriasis: Targets and Therapy
Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy
  • 27 May 2026
  • Psoriasis: Targets and Therapy

FAQs on PSORIASIS-TARGETS AND THERAPY